the eu strategy in horizon2020 to fight poverty related...
TRANSCRIPT
The EU strategy in Horizon2020 to fight
poverty related diseases
Meeting on EDCTP2 French Ministry of Education, Science
and Innovation, Paris 30 June 2017
Line Matthiessen Acting Director
Health Directorate
DG Research & Innovation European Commission
Brussels, Belgium
• The EU is the world's 2nd largest public funder of research on poverty-related and neglected infectious diseases
The involvement of the EU in research and innovation for PRND
Of the top three funders, only the EU significantly increased
funding (+20%) in 2015, due to its expanded contributions under
EDCTP2
Horizon 2020 (2014-2020): The EU funding instrument for PRND
Societal Challenge 1 (SC1) Health, Demographic change and Well being
EUR: 7.4 billion
Collaborative projects Public-private
partnership with big pharma
Public-public partnerships with EU Member States
& beyond
Blue sky research Grants for small businesses
Loans for small and big R&I companies
Knowledge triangle: Higher education,
business, R&I
The fight against PRNDs: one challenge, many instruments
GTBVP
PRND research portfolio in H2020 (MSCA– ERC- SC1) EUR 269 million* (2014-2017)
HIV/AIDS 80 million€ Tuberculosis 49 million€ Malaria 40 million€ NIDs(including ebola and zika) 100 million€
Main areas covered
Basic research - host-pathogen interactions, genomics, mode of transmission, immune modulators Translational research (including early clinical trials) - developement or optimisation of novel diagnostics tools, vaccines, treatment and curative options, Epidemiological research – networks for outbreaks prepareness, infrastructures for data and samples sharing Personalised medicine - development of tools for mHealth
* Not including EDCTP2, IMI2
Collaborative research and Horizon challenge prizes
European and Developing Countries Clinical Trials
Partnership (EDCTP2)
Innovative Medicines Initiative
Public–Private Partnership between the European Union and the pharmaceutical industry association EFPIA
InnovFin ID loans
Main funding instruments under Societal Challenges Health for PRND research
Risk level
Resources required
EC funding instruments for feeding the pipeline
PUSH
PULL
Discovery,
PoC Preclinic
Clinical Phases
1-3
Upscaling
Manufacturing
Uptake Delivery
IMI
InnovFin ID
Horizon Prize
EDCTP Collaborative
research
Collaborative research actions for innovative solutions for PRND
Implemented by DG RTD
With option of emergency procedure w/o call for proposal
Between countries:
Multinational consortia: with at least 3 partners from 28 EU Member States (MS) or
Associated Countries (AC)
Researchers from any country in the world can participate. Low and middle income
countries are eligible for EU funding
Between different types of organizations
public & private sector: universities, research centres, patients
organisations, civil society, industry, SMEs, etc.
Between disciplines
multidisciplinary, translational research
SC1: Collaborative platforms for vaccine development TB, HIV, malaria
TBVAC2020 - €18.2m Advancing novel an
promising TB vaccine candidates from discovery
to preclinical and early clinical development
MultiViVax - €5 m Development of Effective Vaccines against Multiple
Lifecycle Stages of Plasmodium vivax malaria
OptiMalVax - €20m Optimizing a deployable
high efficacy malaria vaccine
EAVI2020 - €23 Develop vaccine platform for novel preventive/therapeutic
vaccine candidates from discovery to early
clinical testing
EMI-TB - €8m Eliciting mucosal
immunity in tuberculosis
EHVA - €22.2m Develop Multidisciplinary
Vaccine Platform for prophylactic and therapeutic HIV Vaccines candidates and assays for identification of
immune correlates
Feeding the pipeline for EDCTP2
A New Financial Instrument for Infectious Diseases R&D
• Jointly developed by the European Commission and European Investment Bank
• Provides loans between EUR 7.5m and EUR 75m to innovative players active in developing vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases
• No calls – demand-driven
• Launched 15 June 2015 in Riga during 'The First Innovative Enterprise Week'
*http://www.eib.org/products/blending/innovfin
InnovFin loans signed so far…
CAVIDI (Swedish SME) €10 million loan
Allows Cavidi to develop an automated, high-throughput version of a low-cost HIV viral load testing devise validated under a FP7- project
MOBIDIAG (Finnish SME) €15 million loan
Allows to finalise and scale up manufacturing, validation and commercialisation of a diagnostic tool for Infectious Diseases
TRANSGENE (French SME) €20 million loan
Supports the development of innovative treatments for hepatitis B, tuberculosis as well as human papillomavirus-induced cancer
STAT-Diagnostica & Innovation, (Spanish SME) €20 million loan
Supports the development of a new molecular diagnostics device capable of identifying a wide range of infectious pathogens, such as meningitis, respiratory or gastro-intestinal infections.
BiondVax Pharmaceuticals Ltd. (Israeli SME) €20 million loan
Supports the development of a Universal Flu Vaccine candidate
Horizon Prizes
Horizon Prizes are 'challenge' prizes offering a cash reward to whoever can most effectively meet a defined challenge
The aim is to stimulate innovation and come up with solutions to problems that matter to European citizens
A technological or societal challenge is defined without defining the path how to reach it
The contestants are free to come up with the most promising and effective solution within a given deadline
The prize is awarded for the best delivered breakthrough solution in a competitive contest
Birth Day Prize
• Approximately 300,000 women died from preventable causes related to pregnancy and childbirth in 2013
• Maternal and perinatal conditions are the seventh contributors to the global burden of disease
Horizon Prize on reducing maternal and new-born morbidity and
mortality – the Birth Day Prize
• The prize calls for a novel solution to improve the outcome of facility-based deliveries (of a clinical, technological or managerial nature, or a combination of these)
• Developed by European Commission, Bill & Melinda Gates Foundation, and MSD for Mothers programme of Merck Sharp & Dohme Corporation
• More details: www.ec.europa.eu/horizonprize/birthday • deadline 6th September 2017. From the EC: 1 million €
Multi- funders initiatives on infectious diseases
http://www.glopid-r.org/
http://www.edctp.org
GTBVP
http://www.jpiamr.eu/
http://cepi.net/
Global Research Collaboration for Infectious Diseases Preparedness - Objectives
Facilitate exchange of information in outbreak situations
Establish a response plan and a strategic agenda for a coordinated and rapid research response
Address scientific, legal, ethical and financial challenges to a rapid response
Connect infectious disease research networks
Supports public health decision-making
Is NOT a new funding organisation
www.glopid-r.org
Members
Observer Status: World Health Organization (WHO)
CANADA
EUROPEAN COMMISSION
FRANCE
SOUTH AFRICA
SOUTH KOREA
AUSTRALIA
BRAZIL
SPAIN
MEXICO THAILAND
ARGENTINA
JAPAN WHO
UNITED KINGDOM
GERMANY
ITALY
NORWAY
INDIA
USA USA
AFRICA
EGYPT
Global collaboration of funding organisations, industry, PPPs, national governments and public and private organisations active in development of TB vaccine R&D To track and collate global TB vaccine strategies, intervention target product profiles, preferred product characteristics, and candidates in discovery, pre-clinical and clinical development Aim to develop and regularly update stage gating criteria suggested for moving TB vaccine candidates through pre-clinical and clinical stages of product development
Global TB Vaccine Partnership (GTBVP)
#EUAMRaction #EUAMRaction #EUAMRaction
#EUAMRaction
ONE HEALTH
MAKING THE EU A BEST PRACTICE REGION ON AMR
• Better evidence and
awareness
• Better coordination and implementation of EU rules
• Better prevention and control
• Better addressing the role of the environment
• A stronger partnership against AMR and better availability of antimicrobials
BOOSTING RESEARCH, DEVELOPMENT AND
INNOVATION ON AMR
• New economic models & incentives
• Better detection and control measures
• New antimicrobials, rapid diagnostic tests, vaccines & alternative therapies
• AMR in the environment
SHAPING THE GLOBAL AGENDA ON AMR
• Stronger EU global presence, partnering
• Stronger bilateral partnership for stronger cooperation
• Cooperating with developing countries
• Developing a global research agenda
Pillar 2 Boosting research, development and innovation
The Commission will:
• Improve knowledge on detection, effective infection control and surveillance
• Develop new therapeutics and alternatives
• Develop new preventive vaccines
• Develop novel diagnostics
• Develop new economic models and incentives
• Close knowledge gaps on AMR in the environment and on how to prevent transmission
• Special attention to WHO's priority list, TB, HIV, malaria and neglected infectious diseases
• Improve global coordination of research activities by promoting dialogue and collaboration between international research initiatives
• Support the establishment of a virtual research institute under JPIAMR
• Continue collaborative research with sub-Saharan Africa in the context of EDCTP, in particular in relation to TB, HIV, malaria and NID
• Foster international research collaboration on AMR in the animal health sector in the STAR-IDAZ International Research Consortium
Please find here the link to the EC press release for the AMR Action Plan: http://europa.eu/rapid/press-release_IP-17-1762_en.htm
The Commission will:
DEVELOPING A GLOBAL RESEARCH AGENDA
THANK YOU